logo
  

Novavax Reports Positive Results From Study Of Influenza, COVID-19 Vaccine Administered Together

Novavax Inc. (NVAX), on Monday announced positive results from a study of its Covid-19 vaccine NVX-CoV2373 and influenza vaccine Seqirus being administered simultaneously.

According to the company, the results suggest simultaneous vaccination may be a "viable immunization strategy."

The protection afforded by the candidate vaccine was consistent with the main study at 87.5% and 89.8% respectively.

As part of Novavax' Phase 3 clinical trial of NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine candidate, in the United Kingdom, 431 volunteers were also enrolled in a co-administration sub-study, led by researchers at St George's, University of London and St George's Hospital, London.

All received an approved seasonal influenza vaccine with approximately half the participants co-vaccinated with NVX-CoV2373 while the remainder received placebo. The study demonstrated that vaccine efficacy appeared to be preserved in those receiving both vaccines compared to those vaccinated with NVX-CoV2373 alone.

Earlier on Monday, Novavax said NVX-CoV2373, its Covid-19 vaccine candidate, met the primary end point in late-stage study. The phase 3 study of NVX-CoV2373, dubbed Prevent-19, showed overall efficiency of 90.4%, achieving its primary endpoint.

"As the next influenza season approaches and people still need a primary COVID-19 vaccine series or a booster, separate healthcare visits to cover both COVID-19 and influenza vaccinations will be burdensome," said Gregory Glenn, M.D., President of Research and Development, Novavax. "As the first clinical study to evaluate safety, immunogenicity, and efficacy of a COVID-19 vaccine when co-administered with a seasonal influenza vaccine, these results demonstrate the promising opportunity for concomitant vaccination, which may improve the uptake of both vaccines."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Flavor maker McCormick & Co., Inc. is recalling certain McCormick and Frank's brand seasoning products citing possible salmonella risk, the U.S. Food and Drug Administration said. The recall involves McCormick Perfect Pinch Italian Seasoning, McCormick Culinary Italian Seasoning and Frank's RedHot Buffalo Ranch Seasoning. Drug major Pfizer Inc. raised Wednesday its outlook for fiscal 2021 earnings and revenues following strong second quarter results that exceeded market estimates. According to the company, the upward revision in full-year outlook, for the second quarter in a row, reflects its updated expectations for contributions to 2021 performance from both BNT162b2, the Pfizer-BioNTech SE COVID-19 vaccine. While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) reaffirmed its adjusted earnings and revenue growth guidance for the full-year 2021. For fiscal 2021, the company now projects earnings in a range of $3.18 to $3.38 per share,...
Follow RTT